nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2022-5-69-76nnp-1894Research ArticleREVIEWSОБЗОРЫCurrent view on the diagnosis and treatment of neuromyelitis optica spectrum disorders exacerbationsСовременные представления о диагностике и терапии обострений заболеваний спектра оптиконевромиелитаhttps://orcid.org/0000-0002-9769-447XКрасновВ. С.KrasnovV. S.

197022, Санкт-Петербург, ул. Льва Толстого, 6–8

6-8, Lev Tolstoy St., St. Petersburg 197022

https://orcid.org/0000-0002-4776-2999ПраховаЛ. Н.PrakhovaL. N.

197376, Санкт-Петербург, ул. Академика Павлова, 9

9, Academician Pavlov St., St. Petersburg 197376

https://orcid.org/0000-0002-6715-8203ТотолянН. А.TotolyanN. A.

197022, Санкт-Петербург, ул. Льва Толстого, 6–8

6-8, Lev Tolstoy St., St. Petersburg 197022

ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава РоссииРоссияAcad. I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Health of RussiaRussian FederationФГБУН «Институт мозга человека им. Н.П. Бехтеревой» Российской академии наукРоссияN.P. Bekhtereva Human Brain Institute, Russian Academy of SciencesRussian Federation2022241020221456976Copyright © Krasnov V.S., Prakhova L.N., Totolyan N.A., 20222022Краснов В.С., Прахова Л.Н., Тотолян Н.А.Krasnov V.S., Prakhova L.N., Totolyan N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/1894

Irreversible neurological deficit and disability in neuromyelitis optica spectrum disorders (NOSD) are formed as a result of exacerbations, which are often life-threatening. Timely diagnosis and treatment of exacerbations is a key task in the management of this category of patients. A unified structured approach to the diagnosis and treatment of NOSD exacerbations has not been developed. The purpose of this article is to analyze the scientific literature data on this issue in order to optimize the diagnostics and treatment of NOSD exacerbations in everyday clinical practice. 

Необратимый неврологический дефицит и инвалидизация при заболеваниях спектра оптиконевромиелита (ЗСОНМ) формируются в результате обострений, которые нередко носят жизнеугрожающий характер. Своевременная диагностика и лечение обострений являются ключевой задачей ведения этой категории пациентов. Единый структурированный подход к диагностике и лечению обострений ЗСОНМ не разработан. Целью настоящей публикации является анализ данных научной литературы по этой проблеме для оптимизации диагностики и терапии обострений ЗСОНМ в повседневной клинической практике. 

заболевание спектра оптиконевромиелитаобострениелечениеneuromyelitis optica spectrum disordersexacerbationtreatment.ReferencesWhittam D, Wilson M, Hamid S, et al. What’s new in neuromyelitis optica? A short review for clinical neurologist. J Neurol. 2017 Nov;264(11):2330-4. doi: 10.1007/s00415-017-8445-8Whittam D, Wilson M, Hamid S, et al. What’s new in neuromyelitis optica? A short review for clinical neurologist. J Neurol. 2017 Nov;264(11):2330-4. doi: 10.1007/s00415-017-8445-8Ma X, Kermode AG, Hu X, Qiu W. NMOSD acute attack: Understanding, treatment and innovative treatment prospect. J Neuroimmunol. 2020 Nov 15; 348:577387. doi: 10.1016/j.jneuroim.2020.577387Ma X, Kermode AG, Hu X, Qiu W. NMOSD acute attack: Understanding, treatment and innovative treatment prospect. J Neuroimmunol. 2020 Nov 15; 348:577387. doi: 10.1016/j.jneuroim.2020.577387Palace J, Lin D-Y, Zeng D, et al. Outcome prediction models in AQP4- IgG positive neuromyelitis optica spectrum disorders. Brain. 2019 May 1;142(5):1310-3. doi: 10.1093/brain/awz054Palace J, Lin D-Y, Zeng D, et al. Outcome prediction models in AQP4- IgG positive neuromyelitis optica spectrum disorders. Brain. 2019 May 1;142(5):1310-3. doi: 10.1093/brain/awz054Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):346-51. doi: 10.1136/jnnp-2017-316286Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):346-51. doi: 10.1136/jnnp-2017-316286Mealy MA, Mossburg SE, Kim SH, et al. Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. Mult Scler Relat Disord. 2019 Feb;28:64-8. doi: 10.1016/j.msard.2018.12.011Mealy MA, Mossburg SE, Kim SH, et al. Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. Mult Scler Relat Disord. 2019 Feb;28:64-8. doi: 10.1016/j.msard.2018.12.011Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses: Therapy of NMO Attacks. Ann Neurol. 2016 Feb;79(2):206-16. doi: 10.1002/ana.24554Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses: Therapy of NMO Attacks. Ann Neurol. 2016 Feb;79(2):206-16. doi: 10.1002/ana.24554Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012 Jun;135(Pt 6):1834-49. doi: 10.1093/brain/aws109Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012 Jun;135(Pt 6):1834-49. doi: 10.1093/brain/aws109Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Aug 15;381(7):614-25. doi: 10.1056/NEJMoa1900866Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Aug 15;381(7):614-25. doi: 10.1056/NEJMoa1900866Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019 Nov 28;381(22):2114-24. doi: 10.1056/NEJMoa1901747Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019 Nov 28;381(22):2114-24. doi: 10.1056/NEJMoa1901747Tramboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disoder: a randomised, double-blind, multicentre, placebo-conroled phase 3 trial. Lancet Neurol. 2020 May;19(5):402-12. doi: 10.1016/S1474-4422(20)30078-8Tramboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disoder: a randomised, double-blind, multicentre, placebo-conroled phase 3 trial. Lancet Neurol. 2020 May;19(5):402-12. doi: 10.1016/S1474-4422(20)30078-8Cree BA, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019 Oct 12;394(10206):1352- 63. doi: 10.1016/S0140-6736(19)31817-3Cree BA, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019 Oct 12;394(10206):1352- 63. doi: 10.1016/S0140-6736(19)31817-3Ciron J, Audoin B, Bourre B, et al. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Rev Neurol (Paris). 2018 Apr;174(4):255-64. doi: 10.1016/j.neurol.2017.11.005Ciron J, Audoin B, Bourre B, et al. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Rev Neurol (Paris). 2018 Apr;174(4):255-64. doi: 10.1016/j.neurol.2017.11.005Gao F, Chai B, Gu C, et al. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol. 2019 Mar 6;19(1):36. doi: 10.1186/s12883-019-1261-2Gao F, Chai B, Gu C, et al. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol. 2019 Mar 6;19(1):36. doi: 10.1186/s12883-019-1261-2Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014 Mar;71(3):324-30. doi: 10.1001/jamaneurol.2013.5699Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014 Mar;71(3):324-30. doi: 10.1001/jamaneurol.2013.5699Nikoo Z, Badihian S, Shaygannejad V, et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017 Sep;264(9):2003-9. doi: 10.1007/s00415- 017-8590-0. Epub 2017 Aug 22.Nikoo Z, Badihian S, Shaygannejad V, et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017 Sep;264(9):2003-9. doi: 10.1007/s00415- 017-8590-0. Epub 2017 Aug 22.Songwisit S, Kosiyakul P, Jitprapaikulsan J, et al. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and metaanalysis. Sci Rep. 2020 Oct 7;10(1):16727. doi: 10.1038/s41598-020-73882-8Songwisit S, Kosiyakul P, Jitprapaikulsan J, et al. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and metaanalysis. Sci Rep. 2020 Oct 7;10(1):16727. doi: 10.1038/s41598-020-73882-8Kleiter I, Gahlen A, Borisow N, et al. Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e504. doi: 10.1212/NXI.0000000000000504Kleiter I, Gahlen A, Borisow N, et al. Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e504. doi: 10.1212/NXI.0000000000000504Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021 Jan;20(1):60-7. doi: 10.1016/S1474-4422(20)30392-6Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021 Jan;20(1):60-7. doi: 10.1016/S1474-4422(20)30392-6Wallach AI, Tremblay M, Kister I. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder. Neurol Clin. 2021 Feb;39(1):35-49. doi: 10.1016/j.ncl.2020.09.003Wallach AI, Tremblay M, Kister I. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder. Neurol Clin. 2021 Feb;39(1):35-49. doi: 10.1016/j.ncl.2020.09.003Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010 Aug;17(8):1019-32. doi: 10.1111/j.1468-1331.2010.03066.xSellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010 Aug;17(8):1019-32. doi: 10.1111/j.1468-1331.2010.03066.xTrebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014 Jan;261(1):1-16. doi: 10.1007/s00415-013-7169-7Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014 Jan;261(1):1-16. doi: 10.1007/s00415-013-7169-7Weinshenker BG, Wingerchuk DM. Neuromyelitis spectrum disorders. Mayo Clin Proc. 2017 Apr;92(4):663-79. doi: 10.1016/j.mayocp.2016.12.014Weinshenker BG, Wingerchuk DM. Neuromyelitis spectrum disorders. Mayo Clin Proc. 2017 Apr;92(4):663-79. doi: 10.1016/j.mayocp.2016.12.014Bizzoco E, Lolli F, Repice AM, et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol. 2009 Nov;256(11):1891-8. doi: 10.1007/s00415-009-5171-x. Epub 2009 May 28.Bizzoco E, Lolli F, Repice AM, et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol. 2009 Nov;256(11):1891-8. doi: 10.1007/s00415-009-5171-x. Epub 2009 May 28.Shosha E, Dubey D, Palace J, et al. Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG–positive NMOSD. Neurology. 2018 Oct 23;91(17): e1642-e1651. doi: 10.1212/WNL.0000000000006392Shosha E, Dubey D, Palace J, et al. Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG–positive NMOSD. Neurology. 2018 Oct 23;91(17): e1642-e1651. doi: 10.1212/WNL.0000000000006392Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983;33(11):1444- 52. doi: 10.1212/wnl.33.11.1444Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983;33(11):1444- 52. doi: 10.1212/wnl.33.11.1444Schwartz СЕ, Stark RB, Stucky BD. Response-shift effects in neuromyelitis optica spectrum disorder: a secondary analysis of clinical trial data. Qual Life Res. 2021 May;30(5):1267- 82. doi: 10.1007/s11136-020-02707-y.56Schwartz СЕ, Stark RB, Stucky BD. Response-shift effects in neuromyelitis optica spectrum disorder: a secondary analysis of clinical trial data. Qual Life Res. 2021 May;30(5):1267- 82. doi: 10.1007/s11136-020-02707-y.56Cree BA, Bennett JL, Sheehan M, et al. Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. Mult Scler. 2016 Jun;22(7):862-72. doi: 10.1177/1352458515620934Cree BA, Bennett JL, Sheehan M, et al. Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. Mult Scler. 2016 Jun;22(7):862-72. doi: 10.1177/1352458515620934Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729Zhang W, Cui L, Zhang, Y, et al. Questioning the existence of monophasic neuromyelitis optica spectrum disorder by defining a novel long-term relapse-free form from a large Chinese population. J Neurol. 2020 Apr;267(4):1197-205. doi: 10.1007/s00415-019-09685-3Zhang W, Cui L, Zhang, Y, et al. Questioning the existence of monophasic neuromyelitis optica spectrum disorder by defining a novel long-term relapse-free form from a large Chinese population. J Neurol. 2020 Apr;267(4):1197-205. doi: 10.1007/s00415-019-09685-3Akaishi T, Nakashima I, Takahashi, T, et al. Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. Neurol Neuroimmunol Neuroinflamm. 2019 Nov 22;7(1):e640. doi: 10.1212/NXI.0000000000000640Akaishi T, Nakashima I, Takahashi, T, et al. Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. Neurol Neuroimmunol Neuroinflamm. 2019 Nov 22;7(1):e640. doi: 10.1212/NXI.0000000000000640Stratos K, Lee L, Dai D, et al. Evaluation of ethnicity as a predictor of diagnostic phenotype and prognosis in neuromyelitis optica spectrum disorder in Toronto. Canada. Mult Scler Relat Disord. 2020 May;40:101950. doi: 10.1016/j.msard.2020.101950Stratos K, Lee L, Dai D, et al. Evaluation of ethnicity as a predictor of diagnostic phenotype and prognosis in neuromyelitis optica spectrum disorder in Toronto. Canada. Mult Scler Relat Disord. 2020 May;40:101950. doi: 10.1016/j.msard.2020.101950Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012 Jan 19;9:14. doi: 10.1186/1742-2094-9-14.33Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012 Jan 19;9:14. doi: 10.1186/1742-2094-9-14.33Akaishi T, Takahashi T, Nakashima I, et al. Repeated follow-up of AQP4-IgG titer by cellbased assay in neuromyelitis optica spectrum disorders (NMOSD). J Neurol Sci. 2020 Mar 15;410:116671. doi: 10.1016/j.jns.2020.116671Akaishi T, Takahashi T, Nakashima I, et al. Repeated follow-up of AQP4-IgG titer by cellbased assay in neuromyelitis optica spectrum disorders (NMOSD). J Neurol Sci. 2020 Mar 15;410:116671. doi: 10.1016/j.jns.2020.116671Klawiter EC, Bove R, Elsone L, et al. High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology. 2017 Nov 28;89(22):2238-44. doi: 10.1212/WNL.0000000000004681Klawiter EC, Bove R, Elsone L, et al. High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology. 2017 Nov 28;89(22):2238-44. doi: 10.1212/WNL.0000000000004681Barros PO, Cassano T, Hygino J, et al. Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. Clin Exp Immunol. 2016 Mar;183(3):480-9. doi: 10.1111/cei.12733.36Barros PO, Cassano T, Hygino J, et al. Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. Clin Exp Immunol. 2016 Mar;183(3):480-9. doi: 10.1111/cei.12733.36Mao-Draayer Y, Thiel S, Mills EA, et al. Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. Nat Rev Neurol. 2020 Mar;16(3):154-70. doi: 10.1038/s41582-020-0313-yMao-Draayer Y, Thiel S, Mills EA, et al. Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. Nat Rev Neurol. 2020 Mar;16(3):154-70. doi: 10.1038/s41582-020-0313-yJitprapaikulsan J, Fryer JP, Majed M, et al. Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. Neurol Neuroimmunol Neuroinflamm. 2020 May 28;7(4):e727. doi: 10.1212/NXI.0000000000000727.37Jitprapaikulsan J, Fryer JP, Majed M, et al. Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. Neurol Neuroimmunol Neuroinflamm. 2020 May 28;7(4):e727. doi: 10.1212/NXI.0000000000000727.37Akaishi T, Takahashi T, Fujihara K, et al. Risk factors of attacks in neuromyelitis optica spectrum disorders. J Neuroimmunol. 2020 Jun 15;343:577236. doi: 10.1016/j.jneuroim.2020.577236Akaishi T, Takahashi T, Fujihara K, et al. Risk factors of attacks in neuromyelitis optica spectrum disorders. J Neuroimmunol. 2020 Jun 15;343:577236. doi: 10.1016/j.jneuroim.2020.577236Kim SH, Jang H, Park NY, et al. Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies. Neurol Neuroimmunol Neuroinflamm. 2021 Feb 23;8(2):e947. doi: 10.1212/NXI.0000000000000947Kim SH, Jang H, Park NY, et al. Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies. Neurol Neuroimmunol Neuroinflamm. 2021 Feb 23;8(2):e947. doi: 10.1212/NXI.0000000000000947Songthammawat T, Srisupa-Olan T, Siritho S, et al. A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX. Mult Scler Relat Disord. 2020 Feb;38:101506. doi: 10.1016/j.msard.2019.101506Songthammawat T, Srisupa-Olan T, Siritho S, et al. A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX. Mult Scler Relat Disord. 2020 Feb;38:101506. doi: 10.1016/j.msard.2019.101506Li X, Tian D-C, Fan M, et al. Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD). Mult Scler Relat Disord. 2020 Sep;44:102325. doi: 10.1016/j.msard.2020.102325.55Li X, Tian D-C, Fan M, et al. Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD). Mult Scler Relat Disord. 2020 Sep;44:102325. doi: 10.1016/j.msard.2020.102325.55Watanabe M, Nakamura Y, Michalak Z, et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology. 2019 Sep 24;93(13):e1299-e1311. doi: 10.1212/WNL.0000000000008160Watanabe M, Nakamura Y, Michalak Z, et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology. 2019 Sep 24;93(13):e1299-e1311. doi: 10.1212/WNL.0000000000008160Wei Y, Chang H, Li X, et al. CSFS100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders. Biomed Res Int. 2018 Oct 22;2018:5381239. doi: 10.1155/2018/5381239Wei Y, Chang H, Li X, et al. CSFS100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders. Biomed Res Int. 2018 Oct 22;2018:5381239. doi: 10.1155/2018/5381239Wang Y, Zhang L, Zhang B, et al. Comparative clinical characteristics of neuromyelitis optica spectrum disorders with and without medulla oblongata lesions. J Neurol. 2014 May;261(5):954-62. doi: 10.1007/s00415-014-7298-7Wang Y, Zhang L, Zhang B, et al. Comparative clinical characteristics of neuromyelitis optica spectrum disorders with and without medulla oblongata lesions. J Neurol. 2014 May;261(5):954-62. doi: 10.1007/s00415-014-7298-7Nakamura Y, Liu Z, Fukumoto S, et al. Spinal cord involvement by atrophy and associations with disability are different between multiple sclerosis and neuromyelitis optica spectrum disorder. Eur J Neurol. 2020 Jan;27(1):92- 9. doi: 10.1111/ene.14038Nakamura Y, Liu Z, Fukumoto S, et al. Spinal cord involvement by atrophy and associations with disability are different between multiple sclerosis and neuromyelitis optica spectrum disorder. Eur J Neurol. 2020 Jan;27(1):92- 9. doi: 10.1111/ene.14038Contentti EC, Rojas JI, Cristiano E, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Mult Scler Relat Disord. 2020 Oct;45:102428. doi: 10.1016/j.msard.2020.102428Contentti EC, Rojas JI, Cristiano E, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Mult Scler Relat Disord. 2020 Oct;45:102428. doi: 10.1016/j.msard.2020.102428Qin C, Tao R, Zhang SQ, et al. Predictive Factors of Resistance to High-Dose Steroids Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorder. Front Neurol. 2020 Nov 12;11:585471. doi: 10.3389/fneur.2020.585471Qin C, Tao R, Zhang SQ, et al. Predictive Factors of Resistance to High-Dose Steroids Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorder. Front Neurol. 2020 Nov 12;11:585471. doi: 10.3389/fneur.2020.585471Lange C, Feltgen N, Junker B, et al. Resolving the clinical acuity categories “hand motion” and “counting fingers” using the freiburg visual acuity test (FrACT). Graefes Arch Clin Exp Ophthalmol. 2009 Jan;247(1):137- 42. doi: 10.1007/s00417-008-0926-0.62Lange C, Feltgen N, Junker B, et al. Resolving the clinical acuity categories “hand motion” and “counting fingers” using the freiburg visual acuity test (FrACT). Graefes Arch Clin Exp Ophthalmol. 2009 Jan;247(1):137- 42. doi: 10.1007/s00417-008-0926-0.62Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: Review and recommendations. Mult Scler Relat Disord. 2012 Oct;1(4):180-7. doi: 10.1016/j.msard.2012.06.00245Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: Review and recommendations. Mult Scler Relat Disord. 2012 Oct;1(4):180-7. doi: 10.1016/j.msard.2012.06.00245Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm. 2019 May 21;6(4):e572. doi: 10.1212/NXI.0000000000000572Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm. 2019 May 21;6(4):e572. doi: 10.1212/NXI.0000000000000572Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler. 2007 Sep;13(8):968-74. doi: 10.1177/1352458507077189Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler. 2007 Sep;13(8):968-74. doi: 10.1177/1352458507077189Abboud H, Petrak A, Mealy M, et al. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Mult Scler. 2016 Feb;22(2):185- 92. doi: 10.1177/1352458515581438.49Abboud H, Petrak A, Mealy M, et al. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Mult Scler. 2016 Feb;22(2):185- 92. doi: 10.1177/1352458515581438.49Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019 Jun;34(3):171-354. doi: 10.1002/jca.21705Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019 Jun;34(3):171-354. doi: 10.1002/jca.21705Lim YM, Pyun SY, Kang BH, et al. Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler. 2013 Aug;19(9):1216-8. doi: 10.1177/1352458512471875Lim YM, Pyun SY, Kang BH, et al. Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler. 2013 Aug;19(9):1216-8. doi: 10.1177/1352458512471875Kim S-H, Kim W, Huh S-Y, et al. Clinical Efficacy of Plasmapheresis in Patients with Neuromyelitis Optica Spectrum Disorder and Effects on Circulating Anti-Aquaporin-4 Antibody Levels. J Clin Neurol. 2013 Jan;9(1):36-42. doi: 10.3988/jcn.2013.9.1.36Kim S-H, Kim W, Huh S-Y, et al. Clinical Efficacy of Plasmapheresis in Patients with Neuromyelitis Optica Spectrum Disorder and Effects on Circulating Anti-Aquaporin-4 Antibody Levels. J Clin Neurol. 2013 Jan;9(1):36-42. doi: 10.3988/jcn.2013.9.1.36Elsone L, Panicker J, Mutch K, et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. 2014 Apr;20(4):501-4. doi: 10.1177/1352458513495938Elsone L, Panicker J, Mutch K, et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. 2014 Apr;20(4):501-4. doi: 10.1177/1352458513495938

The authors declare that there are no conflicts of interest present.